No connection

Search Results

Regulation Score 68 Bullish

Trump Executive Order Accelerates Psychedelic Drug Approvals; AtaiBeckley Shares Surge

Apr 21, 2026 02:11 UTC
ATAI
Short term

A new executive order targeting the acceleration of FDA reviews for psychedelic treatments has triggered a rally in mental health biotech stocks. AtaiBeckley saw its shares climb over 21% as the timeline for breakthrough therapies could shrink to just two months.

  • President Trump directed health regulators to speed up psychedelic drug reviews
  • Review timelines for breakthrough therapies could drop to 1-2 months
  • AtaiBeckley (ATAI) stock rose over 21% on the news
  • AtaiBeckley's BPL-003 nasal spray holds breakthrough therapy status
  • Phase 3 trials for BPL-003 are expected to begin later this year
  • Company market capitalization stands at roughly $1.8 billion

Shares of AtaiBeckley (NASDAQ: ATAI) surged more than 21% on Monday following a directive from President Donald Trump to expedite the regulatory review process for psychedelic treatments aimed at severe mental illnesses. The executive order specifically targets the reduction of evaluation timelines for certain psychedelic compounds. Under the new guidelines, drugs that have already received breakthrough-therapy designations from the U.S. Food and Drug Administration (FDA) may see their review cycles compressed to as little as one to two months. AtaiBeckley, which maintains a market capitalization of approximately $1.8 billion, is positioned as a primary beneficiary of this policy shift. The company is currently developing BPL-003, an investigational nasal spray designed to treat treatment-resistant depression. BPL-003 already holds the breakthrough therapy designation, making it a prime candidate for the accelerated review timeline. The company has indicated that it expects to initiate Phase 3 clinical trials for the drug later this year. Industry participants view the executive order as a formal validation of psychedelic research. By lowering regulatory hurdles and shortening the time-to-market, the order is expected to catalyze investment and development across the mental health biotechnology sector.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Related Articles

Score 35 Bearish

New York Lawmaker Proposes AI Dividend to Offset Automation Job Losses

Apr 21, 04:38

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile